Los Angeles Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$93.6M Buy
744,650
+740,842
+19,455% +$93.1M 0.35% 61
2025
Q1
$421K Sell
3,808
-509,012
-99% -$56.3M ﹤0.01% 793
2024
Q4
$70M Buy
512,820
+92,072
+22% +$12.6M 0.28% 74
2024
Q3
$48.5M Buy
420,748
+363,863
+640% +$41.9M 0.2% 104
2024
Q2
$7.83M Sell
56,885
-188,496
-77% -$26M 0.03% 288
2024
Q1
$33.8M Sell
245,381
-673,010
-73% -$92.8M 0.12% 160
2023
Q4
$121M Buy
918,391
+364,986
+66% +$48.1M 0.45% 52
2023
Q3
$62.3M Buy
553,405
+2,807
+0.5% +$316K 0.26% 78
2023
Q2
$51.9M Sell
550,598
-84,247
-13% -$7.94M 0.21% 98
2023
Q1
$64.3M Sell
634,845
-128,847
-17% -$13M 0.29% 82
2022
Q4
$91.2M Sell
763,692
-28,274
-4% -$3.38M 0.44% 56
2022
Q3
$84.1M Buy
+791,966
New +$84.1M 0.44% 51
2021
Q4
Sell
-14,016
Closed -$1.34M 1449
2021
Q3
$1.34M Sell
14,016
-5,177
-27% -$496K 0.01% 651
2021
Q2
$1.87M Sell
19,193
-36,255
-65% -$3.53M 0.01% 601
2021
Q1
$5.39M Sell
55,448
-90,189
-62% -$8.77M 0.02% 397
2020
Q4
$14M Sell
145,637
-31,120
-18% -$2.98M 0.06% 227
2020
Q3
$17M Buy
176,757
+43,631
+33% +$4.2M 0.08% 186
2020
Q2
$16.2M Buy
133,126
+122,431
+1,145% +$14.9M 0.08% 205
2020
Q1
$926K Buy
10,695
+2,395
+29% +$207K 0.01% 732
2019
Q4
$892K Buy
8,300
+4,730
+132% +$508K ﹤0.01% 871
2019
Q3
$322K Sell
3,570
-14,380
-80% -$1.3M ﹤0.01% 1110
2019
Q2
$1.52M Sell
17,950
-7,060
-28% -$596K 0.01% 713
2019
Q1
$2.2M Buy
25,010
+21,040
+530% +$1.85M 0.01% 631
2018
Q4
$283K Buy
3,970
+1,880
+90% +$134K ﹤0.01% 1124
2018
Q3
$257K Sell
2,090
-3,570
-63% -$439K ﹤0.01% 1269
2018
Q2
$556K Sell
5,660
-2,410
-30% -$237K ﹤0.01% 1105
2018
Q1
$669K Buy
+8,070
New +$669K ﹤0.01% 945